Health
Anakinra shows therapeutic potential in critically ill COVID-19 patients – News-Medical.Net
A team of international scientists recently conducted an open-level clinical trial to investigate the effects of personalized immunotherapy on critically ill COVID-19…
A team of international scientists recently conducted an open-level clinical trial to investigate the effects of personalized immunotherapy on critically ill coronavirus disease 2019 (COVID-19) patients. Their findings suggest that treatment with an interleukin-1 (IL-1) receptor antagonist, anakinra, can improve the clinical output of severe COVID-19 patients. The study is currently available on the medRxiv* preprint server.
Background
Since the emergence of the COVID-19 pandemic caused by severe…
-
Noosa News23 hours agoGyrocopter pilot injured in crash-landing on K’Gari, north of Brisbane
-
Noosa News14 hours agoRevealed: 75 Qld suburbs you could afford to buy in if lending standards drop
-
General8 hours agoFarmers develop ‘autofill’ tech so agricultural robots can operate around the clock
-
General10 hours agoChoosing an online exercise program can be confusing. Here’s what to look out for